Speciality Medicines Ltd
Speciality Medicines Ltd (SPML) last reported results for the quarter ended Mar 2026, with sales of ₹45 crore and net profit of ₹8 crore. The stock last traded at ₹166, a market capitalisation of ₹145 crore, on a P/E of 11.2. Over the past 52 weeks the stock has ranged between ₹121 and ₹381. Figures are as of 6 Oct 2026 and are not real time.
Speciality Medicines Ltd share price and key metrics
- Current price
- ₹166
- Market cap
- ₹145 cr
- Stock P/E
- 11.2
- Book value
- ₹81
- ROE
- 25.6%
- ROCE
- 25.2%
- Dividend yield
- 0.00%
- 52w high / low
- 381/121
Metrics as of 6 Oct 2026. Not real time.
Track Speciality Medicines Ltd
Cruxal reads every Speciality Medicines Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Speciality Medicines Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 48%
- TTM
- 29%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 98%
- TTM
- 81%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- %
- 10 Years
- %
- 5 Years
- 29%
- 3 Years
- 27%
- Last Year
- 26%
Speciality Medicines Ltd quarterly results
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 31 | 45 |
| Expenses | 26 | 36 |
| Operating profit | 4 | 8 |
| OPM % | 14% | 19% |
| Other income | 0 | 1 |
| Interest | 0 | 1 |
| Depreciation | 0 | 0 |
| Profit before tax | 4 | 8 |
| Tax % | 36% | -1% |
| Net profit | 3 | 8 |
| EPS (₹) | 4.16 | 9.31 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Speciality Medicines Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 40 | 23 | 28 | 58 | 75 |
| Operating profit | 2 | 4 | 5 | 9 | 14 |
| OPM % | 6% | 15% | 19% | 16% | 18% |
| Net profit | 1 | 2 | 3 | 7 | 13 |
| EPS (₹) | 70.48 | 4.42 | 5.73 | 11.19 | 14.83 |
TTM is the trailing twelve months to the most recent quarter.
Speciality Medicines Ltd balance sheet
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 0.21 | 4 | 5 | 6 | 9 |
| Reserves | 2 | 2 | 10 | 24 | 62 |
| Borrowings | 1 | 4 | 3 | 5 | 7 |
| Other liabilities | 3 | 4 | 5 | 4 | 17 |
| Total liabilities | 6 | 13 | 23 | 40 | 95 |
| Fixed assets | 2 | 2 | 1 | 2 | 2 |
| CWIP | 0 | 0 | 0 | -0 | -0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other assets | 4 | 11 | 21 | 38 | 93 |
| Total assets | 6 | 13 | 23 | 40 | 95 |
As reported by the company. Total assets equal total liabilities by construction.
Speciality Medicines Ltd cash flow
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | 1 | -4 | -5 | -6 | -1 |
| Cash from investing | -2 | 0 | -0 | -1 | -3 |
| Cash from financing | 2 | 4 | 5 | 8 | 28 |
| Net cash flow | 0 | 0 | -0 | 1 | 24 |
| Free cash flow | -1 | -4 | -5 | -7 | -1 |
| CFO / operating profit | 36% | -101% | -66% | -54% | -9% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Speciality Medicines Ltd operating ratios
| Per year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | — | 52% | 38% | 34% | 25% |
| Debtor days | 23 | 87 | 142 | 60 | 128 |
| Inventory days | 5 | 103 | 161 | 150 | 191 |
| Days payable | 12 | 40 | 48 | 8 | 80 |
| Cash conversion cycle | 16 | 149 | 255 | 202 | 239 |
| Working capital days | -3 | 76 | 185 | 181 | 221 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Speciality Medicines Ltd shareholding pattern
| % held | Mar 2026 |
|---|---|
| Promoters | 43.43% |
| FIIs | 0.24% |
| Public | 56.34% |
| No. of shareholders | 757 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Speciality Medicines Ltd corporate filings
- We hereby submit intimation regarding closure of trading Window for the Half year ended on September, 30 2026.Insider Trading / SASTlow impact
- Speciality Medicines Limited concludes 5th AGM with unanimous shareholder approval for financial statements and director re-appointmentAGM/EGMlow impact
Cruxal's analysis: Speciality Medicines Limited has successfully concluded its 5th Annual General Meeting…
Read the full analysis - Speciality Medicines Limited Reports Strong FY26 Growth with 81% PAT Surge and Strategic R&D ExpansionAGM/EGMhigh impact
Cruxal's analysis: Speciality Medicines Limited reported robust FY26 financial performance, with revenue…
Read the full analysis - Speciality Medicines Ltd announces 5th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Speciality Medicines Ltd has published the notice for its 5th Annual General Meeting in…
Read the full analysis - Speciality Medicines Ltd submits Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Speciality Medicines Ltd has filed its Annual Report for the financial year 2025-26 as…
Read the full analysis - Speciality Medicines Limited Announces 5th Annual General Meeting Scheduled for September 28, 2026AGM/EGMlow impact
Cruxal's analysis: Speciality Medicines Limited has issued the formal notice for its 5th Annual General…
Read the full analysis - Speciality Medicines Limited Announces 5th Annual General Meeting for September 28, 2026Otherslow impact
Cruxal's analysis: Speciality Medicines Limited has formally announced the scheduling of its 5th Annual…
Read the full analysis - Speciality Medicines Ltd receives regulatory approval for two new products in EthiopiaCompany Updatelow impact
Cruxal's analysis: Speciality Medicines Ltd has announced the receipt of regulatory approval for two new…
Read the full analysis - Speciality Medicines Ltd receives regulatory approval for two new products in EthiopiaCompany Updatemedium impact
Cruxal's analysis: Speciality Medicines Limited has announced the receipt of regulatory approval for two new…
Read the full analysis - Speciality Medicines Limited Appoints Capital Bridge Advisory Service as Investor and Public Relations AgencyCompany Updatelow impact
Cruxal's analysis: Speciality Medicines Limited has announced the appointment of Capital Bridge Advisory…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.